CSL222
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for CSL222, covering 2026-04-16 to 2026-04-16. Get the full timeline:
Most recent: Clinical Trial Update: Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B [Phase 3]